mirtazapine | CARLAT PUBLISHING

Research Update

Mirtazapine Augmentation in OCD

November 9, 2023

Kate J. Travis, MD

Kate J. Travis, MD. Dr. Travis has no financial relationships with companies related to this material.

In theory, mirtazapine may worsen OCD, or it may help. This first-of-its-kind trial puts it to the randomized test.

10 Psychopharm Commandments: Med Withdrawal

September 26, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

When to stop meds quickly, and when to do it slowly, in #2 of our 10 Commandment series.

Management of Psychogenic Polydipsia

July 11, 2022

Victoria Hendrick, MD and Zachary Davis

Psychogenic polydipsia (PP), also known as primary polydipsia and potomania, was first described in the 1930s. It is surprisingly common with a prevalence rate between 3 to 25% in institutionalized patients. In this podcast, we will discuss how to accurately diagnose and manage psychogenic polydipsia in patients.

Comparison of GI Side Effects of Antidepressants

August 3, 2021

Jesus Ligot, MD.

Jesus Ligot, MD. Dr. Ligot has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Modern antidepressants are ranked by their risk of GI side effects, with a few surprises baked in.

Two Negative Studies of Mirtazapine and Riluzole for PTSD in Veterans

June 29, 2021

Richard Moldawsky, MD.

Richard Moldawsky, MD. Dr. Moldawsky has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Medications don’t have a good track record in PTSD, particularly in combat related trauma. Here we review two controlled trials where an old standby (mirtazapine) and a hopeful contender (riluzole) come up short.

Optimal Antidepressant Doses in Major Depression

March 9, 2020

Kristen Gardner, PharmD.

Kristen Gardner, PharmD. Dr. Gardner has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

More is not necessarily better in psychopharmacology. Some medications have plateau effect, while others follow a “U-shaped curve,” causing more problems as the dose goes too high. This metaanalysis looked at 77 dose-response trials with antidepressants to quantify their optimal therapeutic window.

Remeron Runs out of Rocket Fuel

September 23, 2019

When a popular antidepressant combination is discredited, what do we do with it? Dr. Aiken sorts through the possibilities for mirtazapine (Remeron) augmentation, and pulls up a few more myths about this medicine.Date Published: 9/23/19Duration: 9 minutes 11 secondsArticle Referenced: "Mirtazapine Augmentation: Running Low on Rocket Fuel," The Carlat Psychiatry...

Mirtazapine Augmentation: Running Low on Rocket Fuel

August 30, 2019

Thomas Jordan, MD and Chris Aiken, MD.

Thomas Jordan, MD and Chris Aiken, MD. Dr. Jordan and Dr. Aiken have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dubbed “California Rocket Fuel” by Stephen Stahl, the combination of venlafaxine and mirtazapine seemed to hit all the right receptors. The hype may have gotten a little ahead of the evidence on this one, however, as three new studies reveal.